Literature DB >> 29737569

Huntington's disease: Current and future therapeutic prospects.

Karl Kieburtz1, Ralf Reilmann2, C Warren Olanow3.   

Abstract

Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable progression. Currently approved therapies are primarily aimed at treating chorea, but do not address the more clinically meaningful motor, behavioral, and cognitive features of the disease. However, there are a number of promising new therapies that are currently being studied in the laboratory, and in the clinic. This article will review the wide variety of therapies currently being tested, the advances in clinical trials and end points, and the many potentially relevant new targets.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's Disease; Therapy

Mesh：

Year:  2018        PMID： 29737569     DOI： 10.1002/mds.27363

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  7 in total

1.  Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment.

Authors:  Pan Chen; Melissa Totten; Ziyan Zhang; Hana Bucinca; Keith Erikson; Abel Santamaría; Aaron B Bowman; Michael Aschner
Journal:  Expert Rev Neurother       Date:  2019-02-21       Impact factor: 4.618

2.  Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.

Authors:  Weiqi Yang; Jingmo Xie; Qiang Qiang; Li Li; Xiang Lin; Yiqing Ren; Wenlei Ren; Qiong Liu; Guomin Zhou; Wenshi Wei; Hexige Saiyin; Lixiang Ma
Journal:  Neurosci Bull       Date:  2019-08-20       Impact factor: 5.203

Review 3.  The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.

Authors:  Moamen Mostafa Asla; Asmaa Ahmed Nawar; Alaa Abdelsalam; Esraa Elsayed; Marwa Abdelazim Rizk; Mohamed Alaa Hussein; Walaa A Kamel
Journal:  Mov Disord Clin Pract       Date:  2021-10-29

4.  Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices.

Authors:  Mark Forrest Gordon; Igor D Grachev; Itzik Mazeh; Yonatan Dolan; Ralf Reilmann; Pippa S Loupe; Shai Fine; Leehee Navon-Perry; Nicholas Gross; Spyros Papapetropoulos; Juha-Matti Savola; Michael R Hayden
Journal:  Digit Biomark       Date:  2019-09-06

Review 5.  In Vitro Blood-Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device.

Authors:  Jin-Ha Choi; Mallesh Santhosh; Jeong-Woo Choi
Journal:  Micromachines (Basel)       Date:  2019-12-24       Impact factor: 2.891

6.  A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.

Authors:  Hongxuan Feng; Xin Hu; Xin Sun; Wang Zheng; Houda G Khaled; Pan P Li; Dobrila D Rudnicki; Wenjuan Ye; Yu-Chi Chen; Noel Southall; Juan Marugan; Christopher A Ross; Marc Ferrer; Mark J Henderson; Russell L Margolis
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

7.  Tolerability and psychological effects of a multimodal day-care rehabilitation program for persons with Huntington's disease.

Authors:  Karin Ringqvist; Kristian Borg; Marika C Möller
Journal:  J Rehabil Med       Date:  2021-01-11       Impact factor: 2.912
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.